More positive findings from biggest psilocybin trial
COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin
December 1, 2021
COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin
MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI
Novel Psychedelic Treatment Approach Bypasses Hallucinogenic Effects to Allow Widespread Adoption Psycheceutical Inc., a private
Clearmind Medicine Engages Bar-Ilan University to Evaluate Anti-Addictive Properties of Clearmind’s Proprietary MEAI Compound Clearmind
Psilocybin Can Reduce Cravings In Alcohol Dependent Rats, And Now We Know Why A study
Psychedelics Use Associated With 55 Percent Decrease In Daily Opioid Consumption, Study Finds A new
How psychedelics help you manage stress Psychedelic drug users had less psychological distress and more
MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures MindMed (MNMD) launched
Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental
COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin
Ketamine rapidly improves cognitive function, making those in suicidal crisis less likely to harm themselves
COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder
atai Life Sciences Announces Supportive Interim Data from First 8-Patient Cohort of Phase 2a Trial
Psilocybin-assisted psychotherapy might help to reduce attachment anxiety A new study suggests that psilocybin therapy
World-first psilocybin clinical trial in the treatment of Generalised Anxiety Disorder receives ethics approval This
Psychedelic Drug in Early Stages of Development Could Have Potential for Postpartum Depression Existing treatments
Clearmind Signs Development and Supply Agreement to Produce its Drug Candidate MEAI Psychedelic Molecule With
Understanding Neuroplasticity Induced by TrYptamines (UNITY) Psychedelics clearly have a huge impact on people with
Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous
Mycrodose Therapeutics and Nova Mentis Announce LOI to Co-Develop Advanced Drug Delivery System According to
New Research Hints at a Link Between Psychedelics and Improved Heart Health Psychedelics improve mental
MYND Diagnostics Inc. Announces Participation in a Monash University (Australia) Proposal for $3 Million Clinical
Mushroom Consumption May Lower Risk of Depression Even non-psychedelic mushrooms could lower your risk of
Novamind Launches New Psychedelic Palliative Care Program Patients in palliative care have higher rates of